<DOC>
	<DOCNO>NCT00806208</DOCNO>
	<brief_summary>A trial ass safety four dos MEDI 507 combine another drug initial treatment least Grade II acute Graft-vs-Host Disease recipient .</brief_summary>
	<brief_title>Trial Evaluation Safety Escalating Dose Levels MEDI-507 Patients Treatment Least Grade II Graft-Versus-Host Disease ( GvHD )</brief_title>
	<detailed_description>The primary objective study assess safety four dose level MEDI 507 combine methylprednisolone initial treatment least Grade II acute GvHD stem cell bone marrow allograft recipient .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1. allogeneic bone marrow hematopoietic stem cell graft recipients 2. acute GvHD least Grade II severity 3. receipt least 2 mg/kg methylprednisolone ( equivalent corticosteroid ) within eight 24 hour prior initial receipt study drug 4. evidence engraftment ( ANC 1,000 cells/mm3 ) 5. histologic evidence GvHD biopsy perform current episode 6. receipt GvHD prophylaxis methotrexate , tacrolimus cyclosporine 7. age least 18 year 8. body weight 130 kg 9 . Both male female eligible , female childbearing potential , unless previously surgically sterilize , agree use effective method birth control ( e.g. , abstinence , intrauterine contraceptive device , oral contraceptive , diaphragm condom combination contraceptive jelly , cream foam , Norplant7 DepoProvera7 ) begin first study injection continue 60 day final study injection . 1. previous receipt MEDI 507 2. diagnosis chronic GvHD 3. previous treatment antiTcell monoclonal antibody OKT73 daclizumab ( Zenapax7 ) 4. receipt antithymocyte globulin ( ATGAM7 ATG ) within 14 day 5. treatment 0.3 mg/kg/day methylprednisolone ( equivalent corticosteroid ) 72 hour treatment GvHD 6. intolerance history intolerance corticosteroid unlikely patient able complete least ten day corticosteroid therapy ( 2 mg/kg/day methylprednisolone equivalent ) 7. one allogeneic bone marrow hematopoietic stem cell allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>